Bruker Corporation (BRKR)

$78.56

-4.38

(-5.28%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Bruker Corporation

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 681.9M → 854.5M (in $), with an average increase of 10.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 57.1M → 205.5M (in $), with an average increase of 46.2% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 30.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 43.5%

Performance

  • $77.12
    $80.90
    $78.56
    downward going graph

    1.83%

    Downside

    Day's Volatility :4.67%

    Upside

    2.89%

    downward going graph
  • $53.65
    $94.86
    $78.56
    downward going graph

    31.71%

    Downside

    52 Weeks Volatility :43.44%

    Upside

    17.18%

    downward going graph

Returns

PeriodBruker CorporationSector (Health Care)Index (Russel 2000)
3 Months
16.0%
-0.7%
0.0%
6 Months
37.84%
6.6%
0.0%
1 Year
1.53%
3.7%
-1.5%
3 Years
23.85%
14.0%
-21.8%

Highlights

Market Capitalization
11.5B
Book Value
$9.49
Dividend Share
0.2
Dividend Yield
0.24%
Earnings Per Share (EPS)
2.9
PE Ratio
28.93
PEG Ratio
3.64
Wall Street Target Price
85.2
Profit Margin
14.41%
Operating Margin TTM
16.06%
Return On Assets TTM
7.7%
Return On Equity TTM
33.67%
Revenue TTM
3.0B
Revenue Per Share TTM
20.25
Quarterly Revenue Growth YOY
20.599999999999998%
Gross Profit TTM
1.3B
EBITDA
599.0M
Diluted Eps TTM
2.9
Quarterly Earnings Growth YOY
1.13
EPS Estimate Current Year
2.74
EPS Estimate Next Year
3.42
EPS Estimate Current Quarter
0.68
EPS Estimate Next Quarter
0.61

Analyst Recommendation

Buy
    64%Buy
    29%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Bruker Corporation(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
5
5
5
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 8.45%

Current $78.56
Target $85.20

Company Financials

FY18Y/Y Change
Revenue
1.9B
↑ 7.34%
Net Income
179.7M
↑ 128.63%
Net Profit Margin
9.48%
↑ 5.03%
FY19Y/Y Change
Revenue
2.1B
↑ 9.34%
Net Income
197.2M
↑ 9.74%
Net Profit Margin
9.51%
↑ 0.03%
FY20Y/Y Change
Revenue
2.0B
↓ 4.11%
Net Income
157.8M
↓ 19.98%
Net Profit Margin
7.94%
↓ 1.57%
FY21Y/Y Change
Revenue
2.4B
↑ 21.66%
Net Income
277.1M
↑ 75.6%
Net Profit Margin
11.46%
↑ 3.52%
FY22Y/Y Change
Revenue
2.5B
↑ 4.67%
Net Income
296.6M
↑ 7.04%
Net Profit Margin
11.72%
↑ 0.26%
FY23Y/Y Change
Revenue
3.0B
↑ 17.14%
Net Income
427.2M
↑ 44.03%
Net Profit Margin
14.41%
↑ 2.69%
Q3 FY22Q/Q Change
Revenue
638.9M
↑ 8.58%
Net Income
88.1M
↑ 77.98%
Net Profit Margin
13.79%
↑ 5.38%
Q4 FY22Q/Q Change
Revenue
708.4M
↑ 10.88%
Net Income
97.4M
↑ 10.56%
Net Profit Margin
13.75%
↓ 0.04%
Q1 FY23Q/Q Change
Revenue
685.3M
↓ 3.26%
Net Income
76.5M
↓ 21.46%
Net Profit Margin
11.16%
↓ 2.59%
Q2 FY23Q/Q Change
Revenue
681.9M
↓ 0.5%
Net Income
57.1M
↓ 25.36%
Net Profit Margin
8.37%
↓ 2.79%
Q3 FY23Q/Q Change
Revenue
742.8M
↑ 8.93%
Net Income
88.1M
↑ 54.29%
Net Profit Margin
11.86%
↑ 3.49%
Q4 FY23Q/Q Change
Revenue
854.5M
↑ 15.04%
Net Income
205.5M
↑ 133.26%
Net Profit Margin
24.05%
↑ 12.19%
FY18Y/Y Change
Total Assets
2.1B
↑ 9.24%
Total Liabilities
1.2B
↑ 0.7%
FY19Y/Y Change
Total Assets
2.8B
↑ 30.2%
Total Liabilities
1.9B
↑ 51.57%
FY20Y/Y Change
Total Assets
3.0B
↑ 9.97%
Total Liabilities
2.1B
↑ 11.75%
FY21Y/Y Change
Total Assets
3.7B
↑ 19.75%
Total Liabilities
2.6B
↑ 23.79%
FY22Y/Y Change
Total Assets
3.6B
↓ 0.86%
Total Liabilities
2.5B
↓ 3.06%
FY23Y/Y Change
Total Assets
4.2B
↑ 17.45%
Total Liabilities
2.8B
↑ 14.07%
Q3 FY22Q/Q Change
Total Assets
3.3B
↓ 1.42%
Total Liabilities
2.4B
↓ 0.46%
Q4 FY22Q/Q Change
Total Assets
3.6B
↑ 8.44%
Total Liabilities
2.5B
↑ 4.34%
Q1 FY23Q/Q Change
Total Assets
3.8B
↑ 4.02%
Total Liabilities
2.6B
↑ 2.67%
Q2 FY23Q/Q Change
Total Assets
3.9B
↑ 2.47%
Total Liabilities
2.6B
↑ 1.62%
Q3 FY23Q/Q Change
Total Assets
3.8B
↓ 1.01%
Total Liabilities
2.6B
↓ 0.79%
Q4 FY23Q/Q Change
Total Assets
4.2B
↑ 11.31%
Total Liabilities
2.8B
↑ 10.2%
FY18Y/Y Change
Operating Cash Flow
239.7M
↑ 55.25%
Investing Cash Flow
-123.4M
↑ 308.61%
Financing Cash Flow
-112.4M
↓ 29.31%
FY19Y/Y Change
Operating Cash Flow
213.4M
↓ 10.97%
Investing Cash Flow
-158.4M
↑ 28.36%
Financing Cash Flow
300.0M
↓ 366.9%
FY20Y/Y Change
Operating Cash Flow
333.2M
↑ 56.14%
Investing Cash Flow
-192.7M
↑ 21.65%
Financing Cash Flow
-161.6M
↓ 153.87%
FY21Y/Y Change
Operating Cash Flow
282.4M
↓ 15.25%
Investing Cash Flow
-192.4M
↓ 0.16%
Financing Cash Flow
318.7M
↓ 297.22%
FY22Y/Y Change
Operating Cash Flow
262.0M
↓ 7.22%
Investing Cash Flow
-251.6M
↑ 30.77%
Financing Cash Flow
-415.2M
↓ 230.28%
Q3 FY22Q/Q Change
Operating Cash Flow
69.5M
↓ 256.53%
Investing Cash Flow
-57.6M
↓ 200.88%
Financing Cash Flow
-82.0M
↑ 2.76%
Q4 FY22Q/Q Change
Operating Cash Flow
159.1M
↑ 128.92%
Investing Cash Flow
-149.3M
↑ 159.2%
Financing Cash Flow
-36.0M
↓ 56.1%
Q1 FY23Q/Q Change
Operating Cash Flow
87.5M
↓ 45.0%
Investing Cash Flow
-108.2M
↓ 27.53%
Financing Cash Flow
-30.7M
↓ 14.72%
Q2 FY23Q/Q Change
Operating Cash Flow
13.0M
↓ 85.14%
Investing Cash Flow
-26.0M
↓ 75.97%
Financing Cash Flow
-10.3M
↓ 66.45%

Technicals Summary

Sell

Neutral

Buy

Bruker Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bruker Corporation
Bruker Corporation
-9.87%
37.84%
1.53%
23.85%
117.29%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bruker Corporation
Bruker Corporation
28.93
28.93
3.64
2.74
0.34
0.08
0.0
9.49
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bruker Corporation
Bruker Corporation
Buy
$11.5B
117.29%
28.93
14.41%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • T. Rowe Price Investment Management,Inc.

    9.58%

  • Vanguard Group Inc

    7.19%

  • BlackRock Inc

    7.14%

  • FMR Inc

    6.85%

  • Pallas Capital Advisors LLC

    6.12%

  • Massachusetts Financial Services Company

    5.87%

Corporate Announcements

  • Bruker Corporation Dividends March,2024

    In the quarter ending March,2024. Bruker Corporation has declared dividend of $0.05

    Read More

Company Information

right from the beginning, which is now more than fifty years ago, bruker has been driven by a single idea: to provide the best technological solution for each analytical task. today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge. bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability. bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers. as one of the world's leading analytical instrumentation companies, bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions. bruker - innovation with integrity. bruker corporation company pages bruker axs: https://www

Organization
Bruker Corporation
Employees
9707
CEO
Dr. Frank H. Laukien Ph.D.
Industry
Health Technology

Discover More

FAQs